Bank of America upped its price target for Vertex Pharmaceuticals from $555 to $567, signaling growing confidence in the ...

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...

Vertex’s effort to provide fertility support services to those on government insurance programs who want to take the ...

Vertex Pharmaceuticals (VRTX) is the second stock to buy for the Nasdaq 100 correction. The biotech stock offers stability ...

It's back and it's live. Amazon's Big Spring Sale launched Tuesday morning and will be running through the end of the month. Officials said the sale will have markdowns on must-have items for the ...

Last year, the company released Vertex AI Search for Healthcare which can be used by developers to build AI apps that help healthcare workers quickly surface information within vast medical databases.

Vertex has established itself as a frontrunner in the indirect tax automation space, serving over 4,800 customers, including more than 60% of the Fortune 500. The company’s solutions are utilized in ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $512.52, indicating a +0.06% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 1.08%.

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next few years, therapeutic ...

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next few years ...

So, you cannot count so much on the two or three times it can bounce back. It starts to just rotate around. If you were so strong that you can make this ball rotate, I mean, have the force to keep it ...

Pilgrim has raised INR 200 Cr in funding via a mix of primary and secondary transactions at a pre-money valuation of INR 3,000 Cr.